NCT07642921Not yet recruiting
HFpEF Phenotyping With Echo, Clinical, and Biomarkers
Phenotyping Heart Failure With Preserved Ejection Fraction (HFpEF) Using Echocardiographic, Clinical, and Biomarker Parameters
Source: ClinicalTrials.gov · Last updated 11 Jun 2026
Brief summary (registry, in English)
The EPIC-HFpEF registry is a nationwide Italian study that follows people with a specific type of heart failure called HFpEF. About 500 patients will be enrolled from several specialized hospitals and monitored for up to two years, without changing their usual treatment. The goal is to better understand this complex condition by identifying different patient "types" based on clinical features, heart imaging, and blood markers. Researchers will also look at how these groups are treated in real life and how their disease progresses over time. By doing this, the study aims to improve how doctors classify and manage HFpEF, moving toward more personalized and effective care for patients in the future.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 23 Mar 2026
- Start date
- 2 Jun 2026
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- University Of Perugia
- Diseases
- Chronic kidney disease, Heart failure, Obesity
- NCT number
- NCT07642921
What you commit to
- Study type: Observational
- Planned participants: 500
- From 2 Jun 2026 to the primary completion date, 30 Jun 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Life expectancy \< 1 year because of non-cardiac causes;
- History of recent (6 months) infective, or inflammatory, autoimmune or neoplastic diseases.
- Myocardial infarction (increase in cardiac enzymes in combination with symptoms of ischemia or newly developed ischemic ECG changes), coronary artery bypass graft surgery or other major cardiovascular surgery, stroke or TIA in past 3 months;
- Chronic pulmonary disease requiring home oxygen, oral steroid therapy or hospitalization for exacerbation within 12 months;
- Congenital heart disease.
- Primary pulmonary hypertension
- Moderate-to-severe degenerative (primary) valve disease
- Implanted cardiac resynchronization therapy (CRT) and/or stable RV pacing.
Lab values
- Stage \>4 CKD (estimated glomerular filtration rate \[eGFR\] \< 15 ml/min/1.73m2),
Other
- Planned participation or participation in a clinical trial;
- Cardiomyopathy based on muscular dystrophies, cardiomyopathy with reversible causes (e.g. stress cardiomyopathy), or known pericardial constriction;
- Implantation of cardioverter defibrillator (ICD) within 3 months
Who the study is looking for
- Patients ≥ 18 years old
- Signed patient informed consent form (ICF)
- Diagnosis of chronic (documented HF hospitalization in the last year) or acute decompensated HF shown by signs and symptoms of HF and LVEF \>50% and, according to guidelines and the universal definition of HF, elevated levels of natriuretic peptides (NT-proBNP ≥300 pg/ml in sinus rhythm or NTproBNP ≥600 pg/ml in atrial fibrillation), at the time of enrolment (10)
- Echocardiographic evidence of increased estimated LV filling pressures according to current guidelines
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.